Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) Profit After Tax: 2013-2025

Historic Profit After Tax for Coherus Oncology (CHRS) over the last 12 years, with Sep 2025 value amounting to -$44.5 million.

  • Coherus Oncology's Profit After Tax rose 6.47% to -$44.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $394.5 million, marking a year-over-year increase of 597.92%. This contributed to the annual value of $28.5 million for FY2024, which is 111.98% up from last year.
  • Coherus Oncology's Profit After Tax amounted to -$44.5 million in Q3 2025, which was down 114.95% from $297.8 million recorded in Q2 2025.
  • Coherus Oncology's 5-year Profit After Tax high stood at $297.8 million for Q2 2025, and its period low was -$172.9 million during Q1 2021.
  • Its 3-year average for Profit After Tax is $14.3 million, with a median of -$44.5 million in 2025.
  • Its Profit After Tax has fluctuated over the past 5 years, first crashed by 586.19% in 2021, then spiked by 642.87% in 2025.
  • Quarterly analysis of 5 years shows Coherus Oncology's Profit After Tax stood at -$45.7 million in 2021, then fell by 28.75% to -$58.9 million in 2022, then plummeted by 35.30% to -$79.7 million in 2023, then soared by 348.34% to $197.8 million in 2024, then increased by 6.47% to -$44.5 million in 2025.
  • Its Profit After Tax was -$44.5 million in Q3 2025, compared to $297.8 million in Q2 2025 and -$56.6 million in Q1 2025.